PD-L1 score among non-small cell lung cancer patients: are we holding out for a hero?
Gilson Gabriel Viana Veloso, Fernanda Telles Lins Taveira, Carlos Gil Ferreira · 2026
Read PD-L1 score among non-small cell lung cancer patients: are we holding out for a hero? by Gilson Gabriel Viana Veloso, Fernanda Telles Lins Taveira, Carlos Gil Ferreira (2026) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/PMC13358842.txt.
Description
Gilson Gabriel Viana Veloso and co-authors question a key lung cancer test in a 2026 commentary. For most patients with non-small cell lung cancer, treatment hinges on a score called PD-L1, which gauges a protein tumors use to hide from the immune system. High scores favor immune drugs. Yet the score is an imperfect hero, the authors argue.
About a fifth to a third of patients score negative, and they tend to respond less well, but some still benefit. The authors discuss new ways to read the marker, including blood-based tests. Their piece urges doctors not to let one score alone decide who receives immune therapy.
Catalog record
| CREATOR | Gilson Gabriel Viana Veloso, Fernanda Telles Lins Taveira, Carlos Gil Ferreira |
|---|---|
| YEAR | 2026 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 12944 |
| LICENSE | https://creativecommons.org/licenses/by/4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |